Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00394251
Status:
COMPLETED
Last Update Posted:
2019-11-25
First Post:
2006-10-30
Brief Title:
Study of Dose-dense Adriamycin Plus Cytoxan AC Followed by Either ABI-007 Abraxane or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Sponsor:
Celgene
Organization:
Celgene
Organization Data
Organization:
Celgene
Class:
INDUSTRY
Study ID:
CA045
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Celgene
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None